Recursion Pharmaceuticals (RXRX) announced significant developments on October 15.There are four main points of interest.1.

The option triggered a $10 million milestone payment to Recursion, bringing total upfront and milestone payments received from Sanofi under the collaboration to $144 million; Recursion is eligible for ...

Life sciences consulting firm Parexel is teaming up with Sanofi to research the role of wearables in clinical trials. While sensor-enabled devices have increasingly featured in a variety of research ...

Recursion (RXRX) stock dips after $200M equity offering despite Sanofi (SNY) choosing its first AI drug candidate under a ...

Recursion Pharmaceuticals stock gained nearly 15% on Thursday thanks to a drug candidate update and milestone payment.

QuantHealth's AI-powered clinical simulator predicts how an individual in a clinical trial will respond to treatment. The aim is to assist pharmaceutical companies in improving their clinical trial ...

TEL AVIV, Isreal & CAMBRIDGE, Mass., October 01, 2025--(BUSINESS WIRE)--QuantHealth, a pioneer in AI-driven clinical trial simulation, announced a strategic investment from Sanofi Ventures, the ...

KT-474 Phase 1 clinical data in HS and AD patients demonstrate robust IRAK4 knockdown in blood and active skin lesions and systemic suppression of proinflammatory cytokines and chemokines with a ...

It’s no secret that drug developers have had a tough time recruiting clinical trial participants. Companies are trying a myriad of approaches to help pharmaceutical companies solve this challenge from ...

(RTTNews) - Medidata, a Dassault Systèmes brand and a leading provider of clinical trial solutions for the life sciences industry, announced an extension of its strategic partnership with Sanofi.

Clinical trial transparency among large pharmaceutical companies is high, although opportunities for improvement remain, according to a study published Tuesday in the BMJ. Researchers from New York ...

The companies will share development and commercialization costs as well as potential future profits from the new drugs, they said.